Related Experiment Videos
Chemotherapy response and resistance
Soyoung Lee1, Clemens A Schmitt
1Max-Delbrück-Center for Molecular Medicine and Charité/Campus, Virchow-Hospital, Department of Hematology/Oncology, Humboldt-University, D-13353 Berlin, Germany.
Abstract:
Apoptosis and premature senescence, an acutely inducible terminal cell-cycle arrest, are known to be the ultimate cellular defense programs that counteract oncogenic transformation. Thus, activated oncogenes may sensitize cells to other stimuli that also recruit these programs. Recent evidence demonstrates that both apoptosis and premature senescence respond to drugs and can therefore contribute to the outcome of cancer therapy. However, manifest malignancies may have acquired mutations that compromise these programs at different levels, and hence may become chemoresistant to varying degrees as a result of defects in either or both programs.
Insights
Cellular defense programs like apoptosis and premature senescence are crucial for preventing cancer. Defects in these pathways can lead to chemotherapy resistance in malignancies.
Area of Science:
- Cellular Biology
- Cancer Research
- Oncology
Background:
- Apoptosis and premature senescence are key cellular defense mechanisms against oncogenic transformation.
- These programs represent terminal cell-cycle arrest and are inducible.
- Recent evidence highlights their role in cancer therapy response.
Purpose of the Study:
- To investigate the role of apoptosis and premature senescence in cancer therapy.
- To understand how defects in these cellular programs contribute to chemoresistance.
Main Methods:
- The study reviews existing evidence on apoptosis and senescence in cancer.
- It analyzes how oncogene activation influences cellular responses.
- The research examines the impact of mutations on these defense mechanisms.
Main Results:
- Activated oncogenes can sensitize cells to stimuli that trigger apoptosis and senescence.
- Both apoptosis and premature senescence are responsive to cancer therapeutic drugs.
- Mutations in malignancies can compromise these programs, leading to varied degrees of chemoresistance.
Conclusions:
- Apoptosis and premature senescence are critical for cancer therapy outcomes.
- Defects in these cellular defense pathways are a significant cause of chemotherapy resistance.
- Understanding these mechanisms is vital for developing more effective cancer treatments.